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The hemostatic system is responsible for limiting blood loss upon vascular injury, and is designed to 
rapidly react to breaches in the endothelial cell lining. Components of this system are subject to 
powerful regulatory mechanisms including various antihemostatic actions of the endothelium, 
antihemostatic actions from proteins in plasma, and blood flow that removes activated hemostatic 
proteins from the growing thrombus. A well-orchestrated balance between pro- and anti-hemostatic 
forces ensures hemostatic balance and avoids spontaneous bleeding or thrombotic episodes. It is 
evident that hemostatic balance is crucial to avoid these complications as evidenced by the pathology 
associated with a deficiency of pro- or anti-coagulant proteins (e.g., severe and spontaneous bleeding 
in hemophilia and substantially elevated thrombotic risk in patients with deficiencies in some of the 
natural anticoagulants). While congenital or acquired disorders may alter multiple components of the 
hemostatic system simultaneously, such complex changes in the hemostatic system may not 
necessarily lead to severe pathology. For example, the complex hemostatic changes in patients with 
liver disease leads to a hemostatic rebalance without a clinical phenotype in many patients, which 
demonstrates the resilience of the hemostatic system (1). Likewise, hemostatic challenges resulting 
from surgery or trauma are not necessarily related to a dismal hemostatic outcome (2,3). In this issue 
of Seminars of Thrombosis and Hemostasis, we explored consequences of remarkable physiological or 
pathological conditions on the hemostatic system. As we will see, some ‘extreme’ conditions may be 
without clinical consequences, while others are related to a substantial risk of bleeding or thrombosis. 
Moreover, a remarkable set of challenges to the hemostatic system, i.e., hemostatic activators or 
inhibitors in a variety of venoms, are potentially useful as therapeutic agents. 
We will start this issue by discussing effects of physiological extremes. First, Kenet and coworkers (4) 
discuss the hemostatic system in the very young. It is well known that the hemostatic system in 
newborns and very young children has a remarkably different composition than that in adults, with 
decreased plasma levels of most of the activators and inhibitors. Despite these differences, most 
children fortunately do well and are in excellent hemostatic balance. The paper by Kenet discusses 
those rare cases in which young children suffer from bleeding or thrombotic complications in the 
context of the concept of developmental hemostasis. Next, Tzoran and coworkers (5) discuss the 
hemostatic changes that occur as a consequence of ageing. As in the very young, the hemostatic 
system in the oldest old is substantially different from younger adults. However, in this population, the 
risk of thrombotic disease increases tremendously, and interactions with chronic illnesses are 
associated with important thrombotic issues. The subsequent ‘extreme condition’ is discussed by Hunt 
(6), who addresses hemostatic changes in extremes of body weight. Very low body weight is 
associated with incompletely characterized hemostatic changes, which include decreased blood cell 
counts and platelet hyperaggregability.  Among the many clinical consequences of severe obesity is a 
hypercoagulable state that is related to an increased risk of venous and arterial thrombosis. The author 
also discusses mechanisms and clinical consequences of the hemostatic changes associated with 
(severe) obesity. The next paper by Kicken and coworkers (7) deals with extreme exertion. The 
authors propose that a hypercoagulable state induced by strenuous exercise is balanced by a 
concomitant development of a hyperfibrinolytic state. However, this compensatory mechanism largely 
disappears during recovery, which may be important in the context of an increased risk of 
cardiovascular events in athletes.  
The next section in this issue discusses hemostatic challenges caused by disease. Levi (8) discusses 
effects of abnormal body temperature on the hemostatic system. Heatstroke is used to provide an 
example of hemostatic changes that may occur as a result of hyperthermia. Heatstroke may lead to 
disseminated intravascular coagulation which may contribute to a dismal outcome. Hypothermia may 
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occur in conditions like trauma or imposed intentionally in order to protect the brain in patients that 
have had a cardiac arrest or acute liver failure. Although hemostatic changes do occur, the clinical 
consequences may be limited. Hoirisch-Clapauch (9) then discusses the risks of bleeding and 
thrombosis related to anxiety. The author puts forward the thought-provoking hypothesis that anxiety 
combined with hypofibrinolytic states (defined as severe depression or a high-carbohydrate, low-
protein, low-fiber diet and a sedentary lifestyle) has a role in the pathogenesis of thrombotic events, 
and that part of these events, currently classified as unprovoked, are in reality provoked by high 
anxiety states. The next paper by Jacob and coworkers (10) deals with the effects of stress on the 
hemostatic system and concludes that the hypercoagulable state induced by stress could be related to a 
combination of neurotransmitters and hormones and the effects of stress on hemodynamics. Vadasz 
and Toubi (11) then discuss the hemostatic changes in allergy, specifically in asthma and chronic 
spontaneous urticaria. The authors show complex hemostatic changes in both disorders and 
demonstrate that these changes are, at least partly, related to the effects of the immune system on 
hemostasis. Subsequently Elbers and coworkers (12) discuss the interplay between thyroid hormones 
and hemostasis, showing that hypothyroidism is associated with hypocoagulability and risk of 
bleeding, and hyperthyroidism with hypercoagulability and risk of venous thrombosis. In addition, the 
paper describes effects of malignant thyroid disease on developing venous thrombosis, which relates 
to local stasis of the blood due to compression effects of the expanding tumor. The next paper by Putri 
and coworkers (13) discusses thrombocytopenia and platelet function defects that are frequent 
complications of tropical diseases such as malaria and Dengue fever. Interestingly, in some tropical 
diseases in which patients commonly develop thrombocytopenia bleeding is rare (e.g. in malaria), 
whether in other diseases bleeding is an important complication of the disease, which may be related 
to preservation of platelet function in malaria. The paper therefore discusses mechanisms and clinical 
consequences of thrombocytopenia and platelet function defects in tropical diseases and highlights the 
difficulties in studying platelet properties in resource-poor countries where these such diseases are 
frequent. A final contribution by Koh and coworkers (14) gives an extensive overview of proteins and 
peptides isolated from different types of venom that interfere with a variety of hemostatic processes. 
The paper also gives an overview on discovery and development of venom-derived antiplatelet, 
anticoagulant, and thrombolytic agents. Venom-derived compounds are not only used in diagnostic 
assays of hemostasis (e.g., ristocetin-induced platelet agglutination or the Russel Viper Venom time), 
but have clear potential as pharmacological agents (e.g., hirudin).  
Taken together, the papers in this issue of the journal highlight subtle or pronounced hemostatic 
effects of a wide variety of physiological or pathological extremes. The clinical consequences 
associated with hemostatic alterations by these extremes may teach us valuable lessons around the 
requirements for hemostatic balance in health and disease. In addition, these reviews accentuate the 
variety of triggers that may alter the hemostatic system, and stress links between physiological or 
pathological conditions and hemostasis that may not be immediately apparent. We sincerely hope you 
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